A Pilot, Exploratory Dose Escalating Study on the Safety, Pharmacodynamics and Preliminary Efficacy of VLX103 in the Treatment of Moderate Alcoholic Steatohepatitis
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2018
Price : $35 *
At a glance
- Drugs Pentamidine (Primary)
- Indications Alcoholic hepatitis
- Focus Adverse reactions
- 25 May 2018 Status changed from recruiting to withdrawn prior to enrolment.
- 30 Jun 2017 New trial record
- 28 Jun 2017 Status changed from not yet recruiting to recruiting.